Skip to content

Anna Lembke

3 papers in the library · 23 citations · publishing 2022-2026

Papers

Trends in hallucinogen‐associated emergency department visits and hospitalizations in California, USA, from 2016 to 2022

Addiction January 11, 2024 Nicolas Garel, Steven Tate, Kristin Nash et al. 23 citations

Hallucinogen-related emergency department visits in California rose 54% from 2016 to 2022 (2260 to 3476 visits), while alcohol-related visits fell 20% and cannabis-related visits rose 15%. Hallucinogen-related hospitalizations increased 55% (2556 to 3965), compared with a 1% increase for both alcohol and cannabis. These trends were statistically different from those for alcohol and cannabis. The absolute numbers remain small, but the relative increase is large.

The Montreal model of ketamine-therapy for alcohol use disorder and comorbid treatment-resistant depression: protocol for a feasibility trial

BMJ Open March 1, 2026 Christina Mcanulty, Philippe Lavoie, Samuel Cyr et al.

A new treatment combining ketamine infusions with acceptance and commitment therapy (ACT) may be feasible for people who have both alcohol use disorder and treatment-resistant depression. In an open-label trial at a Montreal hospital, 30 participants will receive six ketamine infusions plus eight weekly therapy sessions, either in person or online. The study primarily tests whether the combined approach is practical and acceptable by measuring completion rates, safety, and data quality. Exploratory measures will track changes in depressive symptoms, alcohol use, and quality of life. Some participants will also be interviewed about their experiences.

Buprenorphine Microdosing Cross Tapers: A Time for Change

International Journal of Environmental Research and Public Health December 8, 2022 Amer Raheemullah, Ori-Michael Benhamou, Jamie Kuo et al.

Microdosing buprenorphine to transition patients from full-agonist opioids avoids the withdrawal and pain that typically require 12 or more hours of opioid abstinence. Evidence shows this cross-taper strategy is safe and effective, and it is already used across the United States. The authors argue that national prescribing guidelines and buprenorphine training should recognize this approach, and that the FDA should approve transdermal buprenorphine for opioid use disorder while manufacturers produce lower-dose sublingual formulations. They conclude that buprenorphine microdosing cross-tapers should become the new standard of care.